AMOEBA (EPA:AMEBA) - AMOEBA and VISCUS BIOLOGICS announce a joint program for the treatment of multi-resistant bacteria for human wound care

Transparency directive : regulatory news

27/06/2017 17:40

PRESS RELEASE

AMOEBA and VISCUS BIOLOGICS announce a joint program for the treatment of
multi-resistant bacteria for human wound care

Lyon, Cleveland, June 27th, 2017 - AMOEBA (FR0011051598 - AMEBA), producer of a
biological biocide capable of eliminating bacterial risk in water, announced
today the development of a collaboration with VISCUS BIOLOGICS in order to
carry out collective testing on a new wound care application in the field of
human health.

VISCUS BIOLOGICS has a proven expertise in the field of wound care products, in
particular collagen- based dressings, and has already carried out a large
number of projects with commercial partners and research centers in the US and
Europe.

Following preliminary in vitro testing, the two companies intend to extend
their cooperation and further confirm, through additional in vitro and in vivo
testing, the action of the Willaertia magna C2c Maky micro-organism against
certain pathogenic Multi-Drug Resistant (MDR) bacteria that resist multiple
antibiotics. Willaertia magna C2c Maky could therefore be used with advanced
wound care dressings. This project is in the first instance focusing on the US
market.

There is a strong demand in the wound care market to develop innovative
solutions to manage bacterial resistance to antibiotics as alternatives to
commercially available antimicrobial dressings.

In a global advanced wound care market estimated at USD 17 billion1, the
antimicrobial dressing segment represents USD 1.87 billion2 with a potential
CAGR of USD 841 million3 in the USA.

" With this project with AMOEBA, VISCUS BIOLOGICS is aiming to address a very
important market segment in the wound care industry. Willaertia Magna C2c Maky
is a natural predator of bacteria, including pathogenic bacteria. The amoeba
can function as a phagocyte that envelops and dissolves the bacteria internally
while being biocompatible to the surrounding cells and tissue. The Willaertia
Magna C2c Maky amoeba is also effective against biofilms of bacteria, acting to
break down the biofilm. For these reasons, we are studying the effectiveness on
clinically relevant pathogens.

Ultimately, Willaertia magna C2c Maky on its own or in combination with other
treatments may provide another tool for treating wounds that are infected or at
risk of becoming infected. " stated Peter GINGRAS, CEO of VISCUS BIOLOGICS.

" With this collaboration with VISCUS BIOLOGICS, AMOEBA is reaching an
historical turning point in its development. We will be able to contribute to
the advancement of clinical research to meet the global challenge of bacterial
resistance to antibiotics (chemical molecules). Preliminary in vitro testing
supports the use of Willaertia Magna C2c Maky on antibiotic-resistant strains.
This partnership opens new development perspectives for AMOEBA beyond water
treatment, in the chronic wound care market. " added Fabrice PLASSON, CEO of
AMOEBA.

About VISCUS BIOLOGICS:
Viscus Biologics, LLC designs, manufactures and delivers innovative medical
devices with the objective of positively impacting the health and well-being of
patients around the world. It provides biologic extracellular matrix components
and devices to partners under an original design manufacturing business model.
Novel wound care, orthopedic, cardiovascular, and general surgery products are
in the pipeline based upon allograft or xenograft tissue. The company's
headquarters are based in Cleveland (Ohio, USA). Additionally, our close
relationship with our sister company Aran Biomedical offers partners an
integrated approach to the development of products that combine biologics with
synthetic materials. More information on www.viscusbiologics.com.

About AMOEBA:
AMOEBA group's objective is to become the global leader in eliminating
waterborne bacterial risk in water treatment and wound care applications. Our
solutions represent alternatives to chemical products widely used in the
cooling water treatment and the wound care market. In a global market for
chemical biocides estimated to be worth EUR 21 bn(4) AMOEBA is focusing on the
industrial cooling tower application estimated at EUR 1.7 bn(5). Similarly, in
a global wound care market estimated at EUR 15.2bn(1),AMOEBA is targeting the
chronic wound care market in the USA, estimated to be worth EUR 751 million(3).
The use of Willaertia magna C2c Maky in health care products will be subject to
FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological
biocide for water treatment, BIOMEBA, has not yet been granted marketing
authorization in the USA, Europe and Canada. AMOEBA is taking the required
regulatory steps to be granted marketing authorization in those regions for the
use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France),
AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and
joined the CAC(r) Small index on 21st September 2015. More information on
www.amoeba-biocide.com.

(1) marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User
- Global Forecast to 2021," 2016.
(2) M. Diligence, "Wound Management: An $18.5 billion+ worldwide market in
2021," MedMarket Diligence, 10 June 2013. [Online]. Available:
ence.com/2013/06/10/wound-management-an-18-5-billion-worldwide-market-in-2021/.
[Accessed 14 February 2017].
(3) BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017.
(4) : Sources combinées par Amoéba venant des traiteurs d'eau, de Freedonia,
d'Eurostat et MarketsandMarkets
(5) : Données Amoéba combinées à partir des sources : DRIRE 2013, Eurostat,
ARHIA 2013

Contacts:
Amoéba
Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
ggasparetto@actifin.fr

Viscus Biologics
Peter Gingras
President & CEO
Tel. : +1 (0)216-744-2740
peter.gingras@viscusbiologics.com

source : webdisclosure.com

AMOEBA's latest news

07/10/2024 17:45

AMOEBA (EPA:AMEBA) - AMOEBA and VISCUS BIOLOGICS announce a joint program for the treatment of multi-resistant bacteria for human wound care

Transparency directive : regulatory news

AMOEBA's latest news

Other stories